Preclinical data suggest that ARID1A deficiency sensitizes cancer cells to PARP in both in vitro and in vivo models with inhibitors (47, 48, 54, 84, 85), a process mechanistically linked to DNA damage repair (48, 54). This evidence concerns the gene ARID1A and cancer.